Adam Koppel - Jun 3, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Role: Director
Signature: /s/ Adam Koppel
Stock symbol: DRNA
Transactions as of: Jun 3, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/7/2021, 06:50 PM
Previous filing: Jun 1, 2021
Next filing: Jun 14, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise	$0	+3.33K		$0.00	3.33K	Jun 3, 2021	Direct
holding	DRNA	Common Stock						3.08M	Jun 3, 2021	See footnotes	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Restricted Stock Units	Options Exercise	$0	-3.33K	-100%	$0.00^*	0	Jun 3, 2021	Common Stock	3.33K		Direct	F1
transaction	DRNA	Restricted Stock Units	Award	$0	+3.33K		$0.00	3.33K	Jun 3, 2021	Common Stock	3.33K		Direct	F1
transaction	DRNA	Director Stock Option (Right to Buy)	Award	$0	+15K		$0.00	15K	Jun 3, 2021	Common Stock	15K	$30.47	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") that vest in full on the earlier of (i) 12 months from the date of grant and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs do not expire.
F2	This option vests in equal monthly installments over 12 months from the date of grant , provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through each applicable vesting date.
F3	Represents shares of common stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").
F4	Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Koppel is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by the Bain Capital Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.